Gritstone bio Beheer

Beheer criteriumcontroles 2/4

De CEO Gritstone bio is Andrew Allen, benoemd in Aug2015, heeft een ambtstermijn van 9.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.44M, bestaande uit 18.8% salaris en 81.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.53% van de aandelen van het bedrijf, ter waarde € 43.49K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 6.5 jaar.

Belangrijke informatie

Andrew Allen

Algemeen directeur

US$3.4m

Totale compensatie

Percentage CEO-salaris	18.8%
Dienstverband CEO	9.3yrs
Eigendom CEO	1.5%
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	6.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Andrew Allen's beloning veranderd ten opzichte van Gritstone bio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$133m
Mar 31 2024	n/a	n/a	-US$145m
Dec 31 2023	US$3m	US$646k	-US$138m
Sep 30 2023	n/a	n/a	-US$139m
Jun 30 2023	n/a	n/a	-US$130m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$620k	-US$120m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$116m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	US$4m	US$589k	-US$75m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$70m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$2m	US$569k	-US$105m
Sep 30 2020	n/a	n/a	-US$106m
Jun 30 2020	n/a	n/a	-US$107m
Mar 31 2020	n/a	n/a	-US$103m
Dec 31 2019	US$2m	US$533k	-US$94m
Sep 30 2019	n/a	n/a	-US$84m
Jun 30 2019	n/a	n/a	-US$75m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$2m	US$475k	-US$65m
Sep 30 2018	n/a	n/a	-US$65m
Jun 30 2018	n/a	n/a	-US$56m
Mar 31 2018	n/a	n/a	-US$47m
Dec 31 2017	US$592k	US$436k	-US$41m

Compensatie versus markt: De totale vergoeding ($USD 3.44M ) Andrew } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.14K ).

Compensatie versus inkomsten: De vergoeding van Andrew is gestegen terwijl het bedrijf verliesgevend is.

CEO

Andrew Allen (58 yo)

9.3yrs

Tenure

US$3,444,071

Compensatie

Dr. Andrew R. Allen, BM, BCh, MA, MRCP, M.D., Ph D., serves as Independent Director at Verge Analytics, Inc. since September 2021. He has also held clinical development leadership positions at Chiron Corpo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew Allen	Co-Founder	9.3yrs	US$3.44m	1.53% € 43.5k
Erin Jones	Executive VP & COO	3.7yrs	US$1.52m	0.063% € 1.8k
Karin Jooss	Executive VP and Head of Research & Development	3.7yrs	US$1.58m	0.39% € 11.1k
Vassiliki Economides	Executive VP & CFO	3.4yrs	geen gegevens	0.059% € 1.7k
James Cho	Chief Accounting Officer	3.8yrs	geen gegevens	0.070% € 2.0k
George MacDougall	Director of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Stacy Proctor	Executive VP & Chief People Officer	3.3yrs	geen gegevens	geen gegevens
Matthew Hawryluk	Executive VP & Chief Business Officer	9yrs	geen gegevens	0.034% € 965.5

3.7yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2JQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew Allen	Co-Founder	9.3yrs	US$3.44m	1.53% € 43.5k
Elaine Jones	Independent Chairman of the Board	5.2yrs	US$176.00k	0% € 0
Stephen Webster	Independent Director	less than a year	geen gegevens	0.021% € 600.3
Lawrence Corey	Independent Director	2.3yrs	US$132.50k	0% € 0
Timothy Chan	Member of Scientific Advisory Board	7.4yrs	geen gegevens	geen gegevens
Eugene Zhukovsky	Member of Scientific Advisory Board	5.6yrs	geen gegevens	0% € 0
Graham Lord	Member of Scientific Advisory Board	7.4yrs	geen gegevens	geen gegevens
Naiyer Rizvi	Independent Director & Member of Scientific Advisory Board	8.4yrs	US$140.00k	0% € 0
James Gulley	Member of Scientific Advisory Board	7.4yrs	geen gegevens	geen gegevens
Alessandro Sette	Member of Scientific Advisory Board	7.4yrs	geen gegevens	geen gegevens
Shefali Agarwal	Independent Director	3.4yrs	US$138.50k	0% € 0
Clare Fisher	Independent Director	2.8yrs	US$136.50k	geen gegevens

6.5yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2JQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.5 jaar).

Gritstone bio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Less than half of directors are independent

High number of new directors

Gritstone Oncology, Inc. Announces Promotions Within its Leadership Team

Recent updates

Gritstone bio, Inc. Announces Encouraging Updated Interim Phase 2 Data from Ongoing Phase 2 Study Evaluating GRANITE

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index

New major risk - Revenue and earnings growth

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

New major risk - Market cap size

New major risk - Share price stability

Gritstone Bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.31 loss in 2Q 2023)

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Full year 2023 earnings released: US$1.20 loss per share (vs US$1.32 loss in FY 2022)

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.35 loss in 3Q 2022)

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2022)

New major risk - Financial position

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.34 loss in 1Q 2022)

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$1.32 loss per share (vs US$0.95 loss in FY 2021)

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Third quarter 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in 3Q 2021)

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 2Q 2021)

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.16 profit in 1Q 2021)

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

Less than half of directors are independent

Gritstone Bio, Inc. Announces Positive Clinical Results from First Cohort of A Phase 1 Study (CORAL-BOOST) Evaluating A T Cell-Enhanced Self-Amplifying mRNA (SamRNA) Vaccine Against COVID-19

Gritstone bio, Inc Announces Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.69 loss in 3Q 2020)

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

Gritstone Bio, Inc. Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.69 loss in 2Q 2020)

High number of new directors

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Growth Index

First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020)

Full year 2020 earnings released: US$2.79 loss per share (vs US$2.81 loss in FY 2019)

Revenue beats expectations

Gritstone Oncology, Inc. Announces Promotions Within its Leadership Team

Gritstone Oncology, Inc Announces Board Appointments

Executive VP & CTO recently sold €182k worth of stock

Gritstone Oncology, Inc. and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

Gritstone Oncology, Inc. Advances Development of Second Generation Vaccine Against SARS-CoV-2

Gritstone Oncology, Inc. announced that it expects to receive $15.000001 million in funding

New 90-day high: €3.34

Gritstone Oncology, Inc. announced that it expects to receive $110 million in funding from Avidity Partners Management LP, EcoR1 Capital, LLC, Redmile Group, LLC, and other investors

Gritstone Oncology, Inc Announces Resignation of Jean-Marc Bellemin as Chief Financial Officer

New 90-day high: €2.82

Third quarter 2020 earnings released: US$0.69 loss per share

Revenue misses expectations

Gritstone Oncology, Inc. Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE

Gritstone Oncology, Inc.(NasdaqGS:GRTS) dropped from S&P Global BMI Index